On December 19, 2024, Smart Bud released its AI assistant “Bud – Biopharmaceutical” for the biomedical field, while opening its API service (service provided via application program interface).
“Bud – Biomedicine” is based on the smart Bud biomedicine grand model, aiming to innovate users’ information retrieval work in key scenarios such as pharmaceutical competition pattern analysis, clinical trials and evidence-based medicine, sequence and compound patents, policies and access through the new paradigm of AI question-and-answer, and help pharmaceutical companies accelerate the research and development of new drugs and new therapies.
Using a simple and efficient AI conversational interaction, “Budding Biomedicine” can meet the diverse needs of professionals in the biomedical field, whether it is searching for drug mechanisms of action, summarizing the latest cell therapy research, analyzing the market competitiveness of a specific drug, or understanding policies and regulations, providing in-depth analysis and summary, and supporting the review of information sources.
Users can obtain multi-dimensional information such as new drug information, biological sequence information, patent information and chemical structure through natural language dialogue. “Ja-biopharmaceuticals” also supports users to answer questions and analyze relevant policies and regulations in seven,mainstream countries/regions, including China, the United States, Japan, and Europe, including implied preclinical drug approval, clinical trial application,adverse drug reaction monitoring, drug market access declaration, and drug production GPM.
For the four scenarios, “Bud – Biomedicine” also has a deep exploration function, which supports multidimensional analysis based on problems, and constitutes a complete, clear and systematic answer and its mind map. At the same time, it provides a variety of question and answer modes, and users can flexibly choose to question and answer based on the whole network knowledge, academic papers or patent literature.
In the future, “JA-Bio-Medicine” will also launch a personal knowledge base, convert the PDF file uploaded by users into an editable format, extract the key information, and build a personal knowledge base for users.
Related topics
